Ra Medical Systems Named Finalist for TechAmerica Award
Carlsbad , CA - October 14, 2009
Ra Medical Systems is named as a finalist for the prestigious TechAmerica awards. TechAmerica San Diego, the local chapter of a worldwide advocacy group for the high technology industry, announced the finalists for its 16th Annual High Tech awards on Monday.
Representing approximately 1,500 member companies of all sizes from the public and commercial sectors of the economy, TechAmerica is the industry's largest advocacy organization and is dedicated to helping members' top and bottom lines. It has chapters worldwide. TechAmerica was formed by the merger of AeA, ITAA, GEIA, and the Cyber Security Industry Alliance.
Finalists were chosen in nine categories spanning the high technology industry. Ra Medical is one of three finalists in the medical technology category.
“Being selected as a finalist for the TechAmerica award is an honor for our company and validation of the contributions Ra Medical has made in advancing medical technology. Now in our 8 th year of business, Ra Medical is expanding our sales and production teams to meet increased demand for our flagship product, the PHAROS EX-308 for dermatology. We are investing our profits into developing new excimer technology that will enhance our dermatology business and create new products for the larger vascular market,” commented Dean Irwin, Ra Medical’s CEO.
The TechAmerica winners will be announced on Friday, Oct. 30, 2009 at the Hyatt Aventine in La Jolla.
About Ra Medical Systems
Ra Medical Systems, Inc., a privately held medical device company was founded in 2002 to commercialize medical excimer lasers. Based in Carlsbad, CA, the company manufactures and markets excimer laser systems including the PHAROS for the treatment of skin diseases including psoriasis, vitiligo, atopic dermatitis, and leukoderma.
For more information please visit our website: www.ramed.com
For information about TechAmerica please visit www.TechAmerica.org
This media release may contain forward-looking statements regarding, but not limited to, clinical studies and results of those studies, management, market potential, distributor success, market size, international approvals, FDA clearances, marketing, future events and performance of the company, which involve risks and uncertainties that could materially affect actual results. Investors should refer to documents filed with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this media release.
|
